compound introduction
(S)-Mapracorat is a selective and less active glucocorticoid receptor agonist. In Vitro (S)-Mapracorat concentration dependently inhibited TNFα secretion from activated canine PBMC with IC 50 value of approximately 0.2 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Intradermal injection of compound 48/80 (50 μg in 50 μL saline) resulted in a clear wheal and flare reaction over the 60 min observation period. Topical pre-treatment with (S)-Mapracorat (0.1%) leads to significant reduction in the wheal and flare responses compared to vehicle (acetone) treated areas. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
